|
Orthologous residues
|
|
MCM2 (human): S27‑p, MCM2 (mouse): S27‑p, MCM2 (rat): S28‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, western blotting
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CDK7 (human)
|
siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
roscovitine
|
|
|
|
decrease
|
|
|
olomoucine
|
|
|
|
decrease
|
|
|
siRNA
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation, molecular association, regulation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
DNA
|
|
Not reported
|
|
|
|
|
|
Comments:
regulates ATPase activity in vitro
|